Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis

Dandan Sun , Kun Guo , Naixin Liu , Yilin Li , Yuansheng Li , Yan Hu , Shanshan Li , Zhe Fu , Yinglei Wang , Yutong Wu , Yingxuan Zhang , Jiayi Li , Chao Li , Zhuo Wang , Zijian Kang , Jun Sun , Ying Wang , Xinwang Yang

Burns & Trauma ›› 2023, Vol. 11 ›› Issue (1) : tkad035

PDF
Burns & Trauma ›› 2023, Vol. 11 ›› Issue (1) :tkad035 DOI: 10.1093/burnst/tkad035
Research Article
research-article
Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis
Author information +
History +
PDF

Abstract

Background: Wound management of diabetic foot ulcers (DFUs) is a complex and challenging task, and existing strategies fail to meet clinical needs. Therefore, it is important to develop novel drug candidates and discover new therapeutic targets. However, reports on peptides as molecular probes for resolving issues related to DFUs remain rare. This study utilized peptide RL-QN15 as an exogenous molecular probe to investigate the underlying mechanism of endogenous non-coding RNA in DFU wound healing. The aim was to generate novel insights for the clinical management of DFUs and identify potential drug targets. Methods: We investigated the wound-healing efficiency of peptide RL-QN15 under diabetic conditions using in vitro and in vivo experimental models. RNA sequencing, in vitro transfection, quantitative real-time polymerase chain reaction, western blotting, dual luciferase reporter gene detection, in vitro cell scratches, and cell proliferation and migration assays were performed to explore the potential mechanism underlying the promoting effects of RL-QN15 on DFU repair. Results: Peptide RL-QN15 enhanced the migration and proliferation of human immortalized keratinocytes (HaCaT cells) in a high-glucose environment and accelerated wound healing in a DFU rat model. Based on results from RNA sequencing, we defined a new microRNA (miR-4482-3p) related to the promotion of wound healing. The bioactivity of miR-4482-3p was verified by inhibiting and overexpressing miR-4482-3p. Inhibition of miR-4482-3p enhanced the migration and proliferation ability of HaCaT cells as well as the expression of vascular endothelial growth factor B (VEGFB). RL-QN15 also promoted the migration and proliferation ability of HaCaT cells, and VEGFB expression was mediated via inhibition of miR-4482-3p expression by the p38 mitogen-activated protein kinase (p38MAPK) and smad3 signaling pathways. Conclusions: RL-QN15 is an effective molecule for the treatment of DFUs, with the underlying mechanism related to the inhibition of miR-4482-3p expression via the p38MAPK and smad3 signaling pathways, ultimately promoting re-epithelialization, angiogenesis and wound healing. This study provides a theoretical basis for the clinical application of RL-QN15 as a molecular probe in promoting DFU wound healing.

Keywords

RL-QN15 / Diabetic foot ulcer / Wound healing / miR-4482-3p / Vascular endothelial growth factor B / Peptide / Mitogen-activated protein kinase

Cite this article

Download citation ▾
Dandan Sun, Kun Guo, Naixin Liu, Yilin Li, Yuansheng Li, Yan Hu, Shanshan Li, Zhe Fu, Yinglei Wang, Yutong Wu, Yingxuan Zhang, Jiayi Li, Chao Li, Zhuo Wang, Zijian Kang, Jun Sun, Ying Wang, Xinwang Yang. Peptide RL-QN15 promotes wound healing of diabetic foot ulcers through p38 mitogen-activated protein kinase and smad3/miR-4482-3p/vascular endothelial growth factor B axis. Burns & Trauma, 2023, 11 (1) : tkad035 DOI:10.1093/burnst/tkad035

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.

[2]

Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet (London, England). 2005; 366: 1719-24.

[3]

Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293: 217-28.

[4]

Patel S, Srivastava S, Singh MR, Singh D. Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019; 112: 108615.

[5]

Zhu L, Zhong Q, Yang T, Xiao X. Improved therapeutic effects on diabetic foot by human mesenchymal stem cells expressing MALAT1 as a sponge for microRNA-205-5p. Aging. 2019; 11: 12236-45.

[6]

Tellechea A, Bai S, Dangwal S, Theocharidis G, Nagai M, Koerner S, et al. Topical application of a mast cell stabilizer improves impaired diabetic wound healing. The Journal of investigative dermatology. 2020; 140: 901-11.e11.

[7]

Wei ZR, Jian Y. Discussion on surgical treatment mode of diabetic foot wounds. Chinese Journal of Burns and Wounds. 2023; 39: 305-10.

[8]

Strbo N, Yin N, Stojadinovic O. Innate and adaptive immune responses in wound epithelialization. Advances in wound care. 2014; 3: 492-501.

[9]

Pastar I, Stojadinovic O, Yin NC, Ramirez H, Nusbaum AG, Sawaya A, et al. Epithelialization in wound healing: a comprehensive review. Advances in wound care. 2014; 3: 445-64.

[10]

Souren JM, Ponec M, van Wijk R. Contraction of collagen by human fibroblasts and keratinocytes. vitro cellular & developmental biology: journal of the Tissue Culture Association. 1989; 25: 1039-45.

[11]

Piipponen M, Li D, Landén NX. The immune functions of keratinocytes in skin wound healing. Int J Mol Sci. 2020; 21: 8790.

[12]

Goren I, Müller E, Schiefelbein D, Gutwein P, Seitz O, Pfeilschifter J, et al. Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice. The Journal of investigative dermatology. 2009; 129: 752-64.

[13]

Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995; 270: 12607-13.

[14]

Okonkwo UA, DiPietro LA. Diabetes and wound angiogenesis. Int J Mol Sci. 2017; 18: 1419.

[15]

Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. The journal of investigative dermatology Symposium proceedings. 2000; 5: 40-6.

[16]

Yang Z, Hu X, Zhou L, He Y, Zhang X, Yang J, et al. Photodynamic therapy accelerates skin wound healing through promoting re-epithelialization. Burns & trauma. 2021; 9: tkab008.

[17]

Iyer S, Darley PI, Acharya KR. Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity. J Biol Chem. 2010; 285: 23779-89.

[18]

Räsänen M, Sultan I, Paech J, Hemanthakumar KA, Yu W, He L, et al. VEGF-B promotes endocardium-derived coronary vessel development and cardiac regeneration. Circulation. 2021; 143: 65-77.

[19]

Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res. 2003; 93: 114-23.

[20]

Lan CC, Liu IH, Fang AH, Wen CH, Wu CS. Hyperglycaemic conditions decrease cultured keratinocyte mobility: implications for impaired wound healing in patients with diabetes. Br J Dermatol. 2008; 159: 1103-15.

[21]

Hu SC, Lan CE. High-glucose environment disturbs the physiologic functions of keratinocytes: focusing on diabetic wound healing. J Dermatol Sci. 2016; 84: 121-7.

[22]

Wang P, Chen ZH, Jiang LY, Zhou XQ, Jia CY, Xiao HA. Screening, functional analysis and clinical validation of differentially expressed genes in diabetic foot ulcers. Chinese Journal of Burns and Wounds. 2022; 38: 944-51.

[23]

Goodarzi G, Maniati M, Qujeq D. The role of microRNAs in the healing of diabetic ulcers. Int Wound J. 2019; 16: 621-33.

[24]

Ambros V.The functions of animal microRNAs. Nature. 2004; 431: 350-5.

[25]

Bartel DP.MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33.

[26]

Wang W, Yang C, Wang XY, Zhou LY, Lao GJ, Liu D, et al. MicroRNA-129 and-335 promote diabetic wound healing by inhibiting Sp1-mediated MMP-9 expression. Diabetes. 2018; 67: 1627-38.

[27]

Wu Y, Zhang K, Liu R, Zhang H, Chen D, Yu S, et al. MicroRNA-21-3p accelerates diabetic wound healing in mice by downregulating SPRY1. Aging. 2020; 12: 15436-45.

[28]

Yang X, Wang Y, Wu C, Ling EA. Animal venom peptides as a treasure trove for new therapeutics against neurodegenerative disorders. Curr Med Chem. 2019; 26: 4749-74.

[29]

Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018; 61: 1382-414.

[30]

Zhang Y, Wang QQ, Zhao Z, Deng CJ. Animal secretory endolysosome channel discovery. Zool Res. 2021; 42: 141-52.

[31]

Hu Y, Meng B, Yin S, Yang M, Li Y, Liu N, et al. Scorpion venom peptide HsTx2 suppressed PTZ-induced seizures in mice via the circ_0001293/miR-8114/TGF-β2 axis. J Neuroinflammation. 2022; 19: 284.

[32]

Sims EK, Carr ALJ, Oram RA, DiMeglio LA, Evans-Molina C. 100 years of insulin: celebrating the past, present and future of diabetes therapy. Nat Med. 2021; 27: 1154-64.

[33]

Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016; 21: 802-18.

[34]

Wang Y, Feng Z, Yang M, Zeng L, Qi B, Yin S, et al. Discovery of a novel short peptide with efficacy in accelerating the healing of skin wounds. Pharmacol Res. 2021; 163: 105296.

[35]

Qin P, Meng Y, Yang Y, Gou X, Liu N, Yin S, et al. Mesoporous polydopamine nanoparticles carrying peptide RL-QN15 show potential for skin wound therapy. Journal of nanobiotechnology. 2021; 19: 309.

[36]

Qin P, Tang J, Sun D, Yang Y, Liu N, Li Y, et al. Zn(2+) cross-linked alginate carrying hollow silica nanoparticles loaded with RL-QN15 peptides provides promising treatment for chronic skin wounds. ACS Appl Mater Interfaces. 2022; 14: 29491-505.

[37]

Sun H, Wang Y, He T, He D, Hu Y, Fu Z, et al. Hollow polydopamine nanoparticles loading with peptide RL-QN15: a new pro-regenerative therapeutic agent for skin wounds. Journal of nanobiotechnology. 2021; 19: 304.

[38]

Liu N, Li Y, Yang Y, Shu L, Liu Y, Wu Y, et al. OL-FS13 alleviates experimental cerebral ischemia-reperfusion injury. Exp Neurol. 2022; 357: 114180.

[39]

Yin S, Pang A, Liu C, Li Y, Liu N, Li S, et al. Peptide OM-LV20 protects astrocytes against oxidative stress via the ’PAC1R/JNK/TPH1’ axis. J Biol Chem. 2022; 298: 102429.

[40]

Li Y, Jin T, Liu N, Wang J, Qin Z, Yin S, et al. A short peptide exerts neuroprotective effects on cerebral ischemia-reperfusion injury by reducing inflammation via the miR-6328/IKKβ/NF-κB axis. J Neuroinflammation. 2023; 20: 53.

[41]

Fu Z, Sun H, Wu Y, Li C, Wang Y, Liu Y, et al. A cyclic heptapeptide-based hydrogel boosts the healing of chronic skin wounds in diabetic mice and patients. NPG Asia Materials. 2022; 14: 99.

[42]

Zhang Y, Wang Y, Zeng L, Liu Y, Sun H, Li S, et al. Amphibian-derived peptide homodimer OA-GL17d promotes skin wound regeneration through the miR-663a/TGF-β1/Smad axis. Burns & trauma. 2022; 10: tkac032.

[43]

Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014; 31: 817-36.

[44]

Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018; 1411: 153-65.

[45]

Zubair M, Ahmad J. Role of growth factors and cytokines in diabetic foot ulcer healing: a detailed review. Rev Endocr Metab Disord. 2019; 20: 207-17.

[46]

Game FL, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, et al. Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2016; 32: 154-68.

[47]

Ren H, Zhao F, Zhang Q, Huang X, Wang Z. Autophagy and skin wound healing. Burns & trauma. 2022; 10: tkac003.

[48]

Zhang J, Yang P, Liu D, Gao M, Wang J, Yu T, et al. Inhibiting hyper-O-GlcNAcylation of c-Myc accelerate diabetic wound healing by alleviating keratinocyte dysfunction. Burns & trauma. 2021; 9: tkab031.

[49]

Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012; 148: 1172-87.

[50]

Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019; 179: 1033-55.

[51]

Ban E, Jeong S, Park M, Kwon H, Park J, Song EJ, et al. Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020; 121: 109613.

[52]

Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. The Biochemical journal. 2010; 429: 403-17.

[53]

Chen X, Chen J. miR-3188 regulates cell proliferation, apoptosis, and migration in breast cancer by targeting TUSC5 and regulating the p38 MAPK Signaling pathway. Oncol Res. 2018; 26: 363-72.

[54]

Song T, Zhao J, Jiang T, Jin X, Li Y, Liu X. Formononetin protects against balloon injury-induced neointima formation in rats by regulating proliferation and migration of vascular smooth muscle cells via the TGF-β1/Smad3 signaling pathway. Int J Mol Med. 2018; 42: 2155-62.

[55]

McMullen M, Keller R, Sussman M, Pumiglia K. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene. 2004; 23: 1275-82.

[56]

Han SW, Jung YK, Lee EJ, Park HR, Kim GW, Jeong JH, et al. DICAM inhibits angiogenesis via suppression of AKT and p38 MAP kinase signalling. Cardiovasc Res. 2013; 98: 73-82.

[57]

Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res. 2006; 69: 512-9.

[58]

Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, et al. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 2010; 29: 1351-61.

[59]

Kobayashi T, Liu X, Wen FQ, Fang Q, Abe S, Wang XQ, et al. Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun. 2005; 327: 393-8.

[60]

Sun H, Miao C, Liu W, Qiao X, Yang W, Li L, et al. TGF-β1/TβRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages. Biochem Biophys Res Commun. 2018; 497: 583-90.

[61]

Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992; 176: 1375-9.

[62]

Kahlina K, Goren I, Pfeilschifter J, Frank S. p68 DEAD box RNA helicase expression in keratinocytes. Regulation, nucleolar localization, and functional connection to proliferation and vascular endothelial growth factor gene expression. J Biol Chem. 2004; 279: 44872-82.

[63]

Schiefelbein D, Goren I, Fisslthaler B, Schmidt H, Geisslinger G, Pfeilschifter J, et al. Biphasic regulation of HMG-CoA reductase expression and activity during wound healing and its functional role in the control of keratinocyte angiogenic and proliferative responses. J Biol Chem. 2008; 283: 15479-90.

[64]

Mould AW, Greco SA, Cahill MM, Tonks ID, Bellomo D, Patterson C, et al. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res. 2005; 97: e60-70.

PDF

16

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉